Prognostic Value of STMN1 Expression in Non-small Cell Lung Cancer:
A Meta-analysis.
10.3779/j.issn.1009-3419.2024.102.39
- Author:
Mengjie LI
1
;
Qinghua ZHOU
2
Author Information
1. Department of Thoracic Oncology, Tianjin Medical University Cancer Institute & Hospital; National Clinical Research Center for Cancer; Tianjin's Clinical Research Center for Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, China.
2. Lung Cancer Center, West China Hospital, Sichuan University; Sichuan Lung Cancer Institute, Chengdu 610041, China.
- Publication Type:English Abstract
- Keywords:
Lung neoplasms;
Meta-analysis;
Prognosis;
STMN1
- MeSH:
Humans;
Biomarkers, Tumor/metabolism*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Gene Expression Regulation, Neoplastic;
Lung Neoplasms/pathology*;
Prognosis;
Stathmin/metabolism*
- From:
Chinese Journal of Lung Cancer
2024;27(11):826-830
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUND:Lung cancer is one of the malignant tumors with the highest morbidity and mortality rates worldwide, seriously threatening human health. Non-small cell lung cancer (NSCLC) accounts for more than 85% of all lung cancer cases. STMN1 is a microtubule depolymerizing protein widely present in the cytoplasm and its expression level is associated with the prognosis of NSCLC patients. Through meta-analysis, this study aimed to investigate the predictive value of the expression level of STMN1 for the prognosis of lung cancer and screen for tumor markers with high sensitivity and specificity to optimize the whole-process management of lung cancer patients.
METHODS:The PubMed, The Cochrane Library, Embase, WanFang and CNKI databases were searched from the inception to Sep 6, 2024 for relevant literature. The quality of included studies was assessed by the Newcastle-Ottawa Scale (NOS) score. The hazard ratio (HR) with 95%CI was combined to assess the relationship between STMN1 expression and prognostic factors. The prognostic indicators included the overall survival (OS) and disease-free survival (DFS). All statistical analysis was conducted by the STATA 17.0 software.
RESULTS:A total of 5 high-quality studies (NOS score≥6 points) involving 754 patients were enrolled. The pooled results demonstrated that overexpression of STMN1 was significantly related to worse OS (HR=2.28, 95%CI: 1.79-2.91, P<0.001) and DFS (HR=2.14, 95%CI: 1.45-3.17, P<0.001). Overexpression of STMN1 was a risk factor for poor prognosis of NSCLC patients.
CONCLUSIONS:Overexpression of STMN1 is a poor prognostic factor in NSCLC patients. STMN1 may serve as a prognostic biomarker for NSCLC patients. However, more researches are still needed to verify the above findings.
